163 related articles for article (PubMed ID: 19867385)
1. The c3-activator system: an alternate pathway of complement activation.
Götze O; Müller-Eberhard HJ
J Exp Med; 1971 Sep; 134(3):90-108. PubMed ID: 19867385
[TBL] [Abstract][Full Text] [Related]
2. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
[TBL] [Abstract][Full Text] [Related]
3. C3 proactivator convertase and its mode of action.
Müller-Eberhard HJ; Götze O
J Exp Med; 1972 Apr; 135(4):1003-8. PubMed ID: 4111773
[TBL] [Abstract][Full Text] [Related]
4. Studies of the alternate pathway in chelated serum.
Forsgren A; Mclean RH; Michael AF; Quie PG
J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
[TBL] [Abstract][Full Text] [Related]
5. Formation and function of a complex of the C3 proactivator with a protein from cobra venom.
Cooper NR
J Exp Med; 1973 Feb; 137(2):451-60. PubMed ID: 4734404
[TBL] [Abstract][Full Text] [Related]
6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
7. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
8. Alternative complement pathway activity in sera from patients with sickle cell disease.
Koethe SM; Casper JT; Rodey GE
Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
[TBL] [Abstract][Full Text] [Related]
9. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
10. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
12. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
Edens RE; Linhardt RJ; Bell CS; Weiler JM
Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
[TBL] [Abstract][Full Text] [Related]
13. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
14. Complete absence of the third component of complement in man.
Ballow M; Shira JE; Harden L; Yang SY; Day NK
J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
[TBL] [Abstract][Full Text] [Related]
15. The role of properdin in the alternate pathway of complement activation.
Götze O; Müller-Eberhard HJ
J Exp Med; 1974 Jan; 139(1):44-57. PubMed ID: 4808709
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
Webster GF; McArthur WP
Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
[TBL] [Abstract][Full Text] [Related]
17. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
Pangburn MK; Müller-Eberhard HJ
J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
[TBL] [Abstract][Full Text] [Related]
18. Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation.
Kane MA; May JE; Frank MM
J Clin Invest; 1973 Feb; 52(2):370-6. PubMed ID: 4683877
[TBL] [Abstract][Full Text] [Related]
19. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]